Tirofiban indications and usage: Difference between revisions

Latest revision as of 02:53, 22 July 2014

Redirect to:

@@ Line 1: / Line 1: @@
-__NOTOC__
+#REDIRECT [[Tirofiban#Adult Indications and Dosage]]
-{{Tirofiban}}
-{{CMG}}; {{AE}} {{SS}}
-==Indications and Usage==
-AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, [[myocardial infarction]], or[[ refractory ischemia]]/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f | publisher =  | date =  | accessdate = 6 February 2014 }}</ref>
-==References==
-{{Reflist|2}}
-{{Antithrombotics}}
-[[Category:Antiplatelet drugs]]
-[[Category:Cardiovascular Drugs]]
-[[Category:Drugs]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}